Cover Image
市場調查報告書

惡性間皮癌:開發中產品分析

Malignant Mesothelioma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 229749
出版日期 內容資訊 英文 372 Pages
訂單完成後即時交付
價格
Back to Top
惡性間皮癌:開發中產品分析 Malignant Mesothelioma - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 372 Pages
簡介

惡性間皮癌是一種少見的原發性肋膜惡性腫瘤。是常曝露於石棉下產生的癌症。常見的症狀有腹痛、體重減輕、噁心、嘔吐等,也包含貧血、腸道阻塞、胸部疼痛、咯血等。主要的治療方法為化療,放射線治療,外科手術等。

本報告提供惡性間皮癌治療藥的開發情形調查分析,為您彙整開發中產品的概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

惡性間皮癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Kyowa Hakko Kirin
  • Eli Lilly and Company
  • Bayer AG
  • Aeolus Pharmaceuticals, Inc.
  • Bionomics Limited
  • Biotecnol, Inc.
  • Deciphera Pharmaceuticals, LLC
  • Eagle Pharmaceuticals Inc.
  • SentoClone International AB
  • Verastem, Inc.
  • Formula Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • BNC-105
  • FPI-01
  • YS-110
  • BIW-8962
  • Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine
  • ONCOS-102
  • Drug For Mesothelioma
  • Oshadi D + Oshadi R
  • AEOL-10150
  • anetumab ravtansine
  • LY-3023414
  • Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma
  • VS-4718
  • VS-5584
  • BERTA
  • Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma
  • Ad5-SGE-REIC/Dkk3 Gene Therapy
  • pemetrexed disodium
  • Vaccine For Cancer
  • YP-223
  • YYP-218
  • YP-3
  • DP-3975
  • Tb-535C
  • SentoClone

開發中產品的最新趨勢

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7317IDB

Summary

Global Markets Direct's, 'Malignant Mesothelioma - Pipeline Review, H2 2015', provides an overview of the Malignant Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Malignant Mesothelioma Overview
  • Therapeutics Development
    • Pipeline Products for Malignant Mesothelioma - Overview
    • Pipeline Products for Malignant Mesothelioma - Comparative Analysis
  • Malignant Mesothelioma - Therapeutics under Development by Companies
  • Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes
  • Malignant Mesothelioma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Malignant Mesothelioma - Products under Development by Companies
  • Malignant Mesothelioma - Products under Investigation by Universities/Institutes
  • Malignant Mesothelioma - Companies Involved in Therapeutics Development
    • Aduro BioTech, Inc.
    • Advantagene, Inc.
    • Aeolus Pharmaceuticals, Inc.
    • Amphera BV
    • AnGes MG, Inc.
    • arGEN-X BV
    • ArQule, Inc.
    • AVEO Pharmaceuticals, Inc.
    • Bayer AG
    • Berg LLC
    • Biogen, Inc.
    • Bionomics Limited
    • Biotecnol, Inc.
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb Company
    • Calithera Biosciences, Inc.
    • CanBas Co., Ltd.
    • Concordia Healthcare Corp.
    • CritiTech, Inc.
    • Deciphera Pharmaceuticals, LLC
    • Eagle Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • EnGeneIC Ltd
    • F. Hoffmann-La Roche Ltd.
    • Five Prime Therapeutics, Inc.
    • Genelux Corporation
    • GlaxoSmithKline Plc
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals, Inc.
    • MolMed S.p.A.
    • Morphotek, Inc.
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Oxford BioMedica Plc
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Polaris Pharmaceuticals, Inc.
    • Progenra, Inc.
    • Sellas Inc.
    • Sorrento Therapeutics, Inc.
    • Synta Pharmaceuticals Corp.
    • Targovax AS
    • TRACON Pharmaceuticals, Inc.
    • VasGene Therapeutics, Inc.
    • Verastem, Inc.
    • Virttu Biologics Limited
    • Y's Therapeutics Co., Ltd.
  • Malignant Mesothelioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Ad5-SGE-REIC/Dkk3 - Drug Profile
    • AEOL-10150 - Drug Profile
    • alisertib - Drug Profile
    • amatuximab - Drug Profile
    • anetumab ravtansine - Drug Profile
    • ARGX-110 - Drug Profile
    • ascrinvacumab - Drug Profile
    • AV-203 - Drug Profile
    • avelumab - Drug Profile
    • bevacizumab - Drug Profile
    • BG-00001 - Drug Profile
    • BIW-8962 - Drug Profile
    • BMS-986148 - Drug Profile
    • BNC-105 - Drug Profile
    • CB-839 - Drug Profile
    • CBP-501 - Drug Profile
    • Cellular Immunotherapy 2 for Oncology - Drug Profile
    • Cellular Immunotherapy for Cancer - Drug Profile
    • Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile
    • Cellular Immunotherapy to Target CSPG4 for Oncology - Drug Profile
    • CRS-207 - Drug Profile
    • Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile
    • DP-3975 - Drug Profile
    • DPV-001 - Drug Profile
    • E-7449 - Drug Profile
    • FL-118 - Drug Profile
    • FP-1039 - Drug Profile
    • ganetespib - Drug Profile
    • GEN-0101 - Drug Profile
    • Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
    • Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
    • GLONC-1 - Drug Profile
    • GSK-2256098 - Drug Profile
    • HSV-1716 - Drug Profile
    • iCasp9M28z - Drug Profile
    • JTCR-016 - Drug Profile
    • KPT-251 - Drug Profile
    • LY-3023414 - Drug Profile
    • MesoCancerVac - Drug Profile
    • MesoCART - Drug Profile
    • Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
    • MV-NIS - Drug Profile
    • napabucasin - Drug Profile
    • NGR-hTNF - Drug Profile
    • nintedanib - Drug Profile
    • nivolumab - Drug Profile
    • ONCOS-102 - Drug Profile
    • Oshadi D + Oshadi R - Drug Profile
    • OXB-301 - Drug Profile
    • P-0005091 - Drug Profile
    • paclitaxel - Drug Profile
    • pegargiminase - Drug Profile
    • pembrolizumab - Drug Profile
    • pemetrexed disodium - Drug Profile
    • porfimer sodium - Drug Profile
    • rAd-IFN - Drug Profile
    • Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile
    • Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
    • TargomiRs - Drug Profile
    • Tb-535 - Drug Profile
    • tivantinib - Drug Profile
    • trabectedin - Drug Profile
    • TRC-102 - Drug Profile
    • tremelimumab - Drug Profile
    • ubidecarenone - Drug Profile
    • Vaccine for Cancer - Drug Profile
    • Vaccine to Target WT1 for Cancer - Drug Profile
    • Vas-01 - Drug Profile
    • VS-4718 - Drug Profile
    • VS-5584 - Drug Profile
    • YS-110 - Drug Profile
  • Malignant Mesothelioma - Recent Pipeline Updates
  • Malignant Mesothelioma - Dormant Projects
  • Malignant Mesothelioma - Discontinued Products
  • Malignant Mesothelioma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Malignant Mesothelioma, H2 2015
  • Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Malignant Mesothelioma - Pipeline by Aduro BioTech, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Advantagene, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Amphera BV, H2 2015
  • Malignant Mesothelioma - Pipeline by AnGes MG, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by arGEN-X BV, H2 2015
  • Malignant Mesothelioma - Pipeline by ArQule, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Bayer AG, H2 2015
  • Malignant Mesothelioma - Pipeline by Berg LLC , H2 2015
  • Malignant Mesothelioma - Pipeline by Biogen, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Bionomics Limited, H2 2015
  • Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Malignant Mesothelioma - Pipeline by Boston Biomedical, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Malignant Mesothelioma - Pipeline by Calithera Biosciences, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by CanBas Co., Ltd., H2 2015
  • Malignant Mesothelioma - Pipeline by Concordia Healthcare Corp., H2 2015
  • Malignant Mesothelioma - Pipeline by CritiTech, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015
  • Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Eisai Co., Ltd., H2 2015
  • Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2015
  • Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H2 2015
  • Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Malignant Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Genelux Corporation, H2 2015
  • Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • Malignant Mesothelioma - Pipeline by MedImmune, LLC, H2 2015
  • Malignant Mesothelioma - Pipeline by Merck & Co., Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Merck KGaA, H2 2015
  • Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by MolMed S.p.A., H2 2015
  • Malignant Mesothelioma - Pipeline by Morphotek, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Novartis AG, H2 2015
  • Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H2 2015
  • Malignant Mesothelioma - Pipeline by Pfizer Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Pharma Mar, S.A., H2 2015
  • Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Progenra, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Sellas Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H2 2015
  • Malignant Mesothelioma - Pipeline by Targovax AS, H2 2015
  • Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by VasGene Therapeutics, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Verastem, Inc., H2 2015
  • Malignant Mesothelioma - Pipeline by Virttu Biologics Limited, H2 2015
  • Malignant Mesothelioma - Pipeline by Y's Therapeutics Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2015
  • Malignant Mesothelioma - Dormant Projects, H2 2015
  • Malignant Mesothelioma - Dormant Projects (Contd..1), H2 2015
  • Malignant Mesothelioma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Malignant Mesothelioma, H2 2015
  • Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top